AlgaHealth

Your Health, Your Life - Enhanced

AlgaHealth develops ground-breaking products and patented technologies for unique microalgae strains cultivation, and sustainable production of top-quality, high-value ingredients, aimed at multi-billion health and food markets.

9% From funding target

34

Units lefts

$12,000

Minimum investment

53

Days to go
Share
By: Eran Itzkovitch
Public Campaign
Investment:
Company Stage:
Category:
Food & Agro

Campaign Highlights

Campaign Highlights

Clinically proven solution addressing the mega-opportunity of obesity prevention

AlgaHealth (AH) is an Israeli biotech company founded with the mission to become the global leader for sustainable, green production of high-quality, high-value ingredients from microalgae. AH’’s strategy is to bring to market fucoxanthin-based functional ingredients for dietary formulations to nutraceutical manufacturers. Fucoxanthin is a powerful antioxidant that is mostly known for breaking down fat, thus, successfully preventing metabolic syndrome health problems such as obesity, diabetes, cardio-vascular diseases (or problems). AH has developed a patent-protected, tailored manufacturing process for fucoxanthin powders and oleoresins.

A need for efficient and sustainable solutions for algae sources, cultivation and production

The price point for fucoxanthin is very high and the demand is growing. More than 95% of fucoxanthin-containing products are sourced from macro algae (seaweed). It is an extremely inefficient, wasteful process with harsh impact on the environment. It is also affected by seasonality and results in very limited and unpredictable supply. Current sources from seaweed contain dangerous contaminants, such as heavy metals, iodine and other pollutants.

AlgaHealth’s sustainable, efficient, and commercially available production process

AlgaHealth’s microalgae strains contains up to 100 times more fucoxanthin than seaweed. Moreover, the controlled cultivation and production processes enable contaminant-free, high-quality products, representing the next big thing in preventive healthcare. AlgaHealth developed a commercial-ready, high-quality production process to support initial sales in 2021 and forecast growth in 2022 via a growing pipeline of business partners.

Advanced R&D—product pipeline, strain development and cultivation technologies

The company utilizes cutting-edge biotechnology methods to develop new strains, and AI-based production systems to achieve superior production efficiencies—at least 5x times more efficient than current techniques. AlgaHealth has signed R&D cooperation agreements with some of Israel’s leading academic and technological institutes including Hebrew University in Jerusalem, Volcani Center for Agricultural Research, and the Technion.     

Patents and IP, EU Seal of Excellence

AlgaHealth uses advanced growth procedures based on unconventional, patented ideas and IP, which establish the company as an attractive target for investors, buyers, and other potential partners. The company has granted patents in Australia, Japan and provisional patents have already been submitted in several other countries and territories, including the US, Europe, India, Korea and more.

AlgaHealth investment and achievements were recognized by the European Commission’s Horizon 2020—winning the Seal of Excellence in 2020. 

Product pipeline, business partners, and sales activity

AlgaHealth sales activity started in 2021 with initial sales of its DermaXanthin™ product for the cosmetics market—innovative cosmetics ingredients utilizing fucoxanthin’s anti-aging properties. The company started the FDA approval process for its NutriXanthin™ product for the food supplements market, with approval expected by Q1 2022. The company started to build its pipeline of business partners in key markets for the upcoming years, expecting to sign its first commercial agreement in Q4 2021.

Pitch

Pitch

The Idea

The Need

We might think twice about our everyday spending—but when it comes to our health and wellbeing, most people are far more likely to invest. Health and wellbeing expenses are valued, in fact, at hundreds of billions globally, with an ever-growing need for innovative solutions to age-old human problems, such as obesity.

Data shows that, in 2019, 60% of all adults in OECD countries were either overweight or obese, and could suffer related type-2 diabetes, cardiac and vascular failures, meaning a reduction in life expectancy by as much as 4 years. In addition to their reduced life expectancy, they are at high risk of developing severe illnesses such as cancer and dementia. Moreover, it was proven that overweight and obese children are 13% less likely to perform well at school and are less likely to complete higher education.

The Solution

Fucoxanthin is a healthy, highly effective ingredient that can be used to reduce health issues related to metabolic syndrome, such as being overweight or obese, diabetes, cardio-vascular diseases, and other conditions, but its current production processes make it extremely rare and difficult to manufacture at high quality and in large quantities, to meet the vast and growing demand.

AlgaHealth is a biotech company pioneering the development of smart, cost-effective applications of microalgae for the production of nutraceuticals. The company is developing a new source for fucoxanthin from its specially cultivated microalgae, and a new line of products that contain high quantities of it.

Technology

Microalgae in general contain much more fucoxanthin than seaweed, and AlgaHealth’s special strain of microalgae goes further to reach concentrations of up to 100 times more than the current seaweed source.

Additionally, since AlgaHealth’s microalgae are grown in a controlled environment, the product is available year-round and is of high quality and contaminant-free, as well as non-GMO. Growing the microalgae in a controlled, land-based facility and AlgaHealth’s proprietary “agro-manipulations” in its cultivation and production processes allow for easy upscaling and distributed production, which makes it far more sustainable than any current mass production solution.

The technology is based on unique, novel proprietary microalgae strains and innovative, patent-protected processes and solutions—to ensure a stable and sustainable production process, and remove this significant market bottleneck.

AlgaHealth has engaged with some of Israel's leading research institutes including The Hebrew University in Jerusalem, and The Volcani Institute — to conduct ground-breaking research and development projects that will put AlgaHealth years ahead of the competition: microalgae strain development to achieve 3x to 5x the current microalgae production rate, and AI-based real-time sensing, implementing machine learning as part of production control and optimization.

AlgaHealth’s products—NutriXanthin™ and its parallel for cosmetics, DermaXanthin™—are new products featuring an extremely high concentration of fucoxanthin and are best suited for use as ingredients of food supplements and cosmetics products. Moreover, they are unique in not requiring any organic solvents for their production.

DermaXanthin™ will be available to customers in Q4 2021 and NutriXanthin™ in Q1 2022, pending regulatory approval.

 

Among the innovative advantages of AlgaHealth’s tech:

AlgaHealth production process—a positive environmental impact on the ocean floor

Current production of fucoxanthin from macroalgae (seaweed) creates significant damage to the ocean floor, with very low efficiency in the process. In addition, the extraction of fucoxanthin from current sources, both macroalgae and microalgae, requires the use of organic solvents. AlgaHealth’s production processes are “green”, which significantly limits the negative environmental impact and prevents environmental damage, while increasing production substantially.

Team

Team

Eran Itzkovitch
CEO
Biography
20 years’ executive and operational experience in multiple fields. Former CEO of Abundance Ltd – a pioneering Algae startup.

Omer Geva
Chairman
Biography
Entrepreneur, investor, former CEO and chairman of multiple startups with 20 years’ of experience in building companies towards business success and M&A

  • Chairman of the Board
Oran Ayalon
CTO and Co-Founder
Biography
Former CTO of Alga Technologies and Algalo. Over 20 years of experience in biotech R&D. Holds a PhD in biology and chemistry from the Weizmann Institute of Science

  • Founder
Itai Ivry
COO
Biography
30 years’ experience in design and development of microalgae and aquaculture production facilities. Former sr. advisor to Frutarom (IFF)

Hagay Tzur
Board member and Co-Founder
Biography
Former CEO of Alga Technologies. Over 20 years’ experience in management and business development. Proven success in commercialization of microalgae products

  • Founder
  • Partner

Financial data

Financial data

Updates

Updates

Currently there are no updates in this pitch

The financing rounds made through the ExitValley platform are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) to the Israeli companies law - 1965.
Under our model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors which are not qualified investors and the round of financing in not in the format of an offering arrangement ("רכז הצעה") as defined in the securities law
Follow us